Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives

키워드

참고문헌 (91)

1. Jorizzo JL, "Dermatology", pp.681~692 (2018), Elsevier
2. Lewis M, "Fitzpatrick's dermatology", pp.1061~1085 (2019), McGraw-Hill Education
3. Lim D, "Current concepts and advances in dermatomyositis : a dermatological perspective", Clin Exp Rheumatol, 41, pp.359~369 (2023)
4. Bohan A, "Polymyositis and dermatomyositis(first of two parts)", N Engl J Med, 292, pp.344~347 (1975)
5. Dobloug C, "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort", Ann Rheum Dis, 74, pp.1551~1556 (2015)
6. Euwer RL, "Amyopathic dermatomyositis(dermatomyositis siné myositis). Presentation of six new cases and review of the literature", J Am Acad Dermatol, 24, pp.959~966 (1991)
7. Bendewald MJ, "Incidence of dermatomyositis and clinically amyopathic dermatomyositis : a population-based study in Olmsted County, Minnesota", Arch Dermatol, 146, pp.26~30 (2010)
8. Galimberti F, "Clinically amyopathic dermatomyositis : clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort", Br J Dermatol, 174, pp.158~164 (2016)
9. Da Silva DM, "Dermatomyositis : a diagnostic dilemma", J Am Acad Dermatol, 79, pp.371~373 (2018)
10. Ghazi E, "The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum", Clin Exp Rheumatol, 31, pp.128~134 (2013)
11. Hoogendijk JE, "119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands", Neuromuscul Disord, 14, pp.337~345 (2004)
12. Lundberg IE, "2017 European League Against Rheumatism", American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, 2017, pp.76, 1955~1964
13. Mammen AL, "239th ENMC International Workshop: classi¬fication of dermatomyositis, Amsterdam, the Netherlands, 14–16 De¬cember 2018", Neuromuscul Disord, 30, pp.70~92 (2020)
14. Sontheimer RD, "Dermatomyositis : an overview of recent progress with emphasis on dermatologic aspects", Dermatol Clin, 20, pp.387~408 (2002)
15. Patel B, "Applicability of EULAR", ACR classification criteria for dermatomyositis to amyopathic disease, 2018, pp.79, 77~83
16. Fujimoto M, "Recent advances in dermatomyositis-specific autoantibodies", Curr Opin Rheumatol, 28, pp.636~644 (2016)
17. Hamaguchi Y, "Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis : a multicenter cross-sectional study", Arch Dermatol, 147, pp.391~398 (2011)
18. Concha JSS, "Developing classification criteria for skin-predominant dermatomyositis : the Delphi process", Br J Dermatol, 182, pp.410~417 (2020)
19. Ahmed S, "The validity and utility of the Cutaneous Disease Area and Severity Index(CDASI)as a clinical outcome instrument in dermatomyositis : a comprehensive review", Semin Arthritis Rheum, 50, pp.458~462 (2020)
20. Yassaee M, "Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument", Br J Dermatol, 162, pp.669~673 (2010)
21. Carroll CL, "Development and validation of the Dermatomyositis Skin Severity Index", Br J Dermatol, 158, pp.345~350 (2008)
22. Goreshi R, "Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM", J Invest Dermatol, 132, pp.1117~1124 (2012)
23. Tiao J, "The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index(CDASI)among dermatologists, rheumatologists and neurologists", Br J Dermatol, 176, pp.423~430 (2017)
24. Hundley JL, "Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life", J Am Acad Dermatol, 54, pp.217~220 (2006)
25. Anyanwu CO, "Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index : characterizing disease severity and assessing responsiveness to clinical change", Br J Dermatol, 173, pp.969~974 (2015)
26. Ahmed S, "Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis", Br J Dermatol, 182, pp.949~954 (2020)
27. Aggarwal R, "2016 American College of Rheumatology", European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis : an International Myositis Assessment and Clinical Studies Group, Arthritis Rheumatol, pp.2017, 69[DOI]
28. Rider LG, "Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis : Physician and Patient", Parent Global Activity, Manual Muscle Testing(MMT), Health Assessment Questionnaire(HAQ), Arthritis Care Res (Hoboken), pp.2011, 11[DOI]
29. Pandya R, "Validation of Cutaneous Dermatomyositis Disease Area and Severity Index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial", J Invest Dermatol, 143, pp.2378~2385 (2023)
30. Pandya R, "A revised outcome measure for dermatomyositis clinical trials: the Dermatomyositis Outcomes for Muscle and Skin (DMOMS)", ACR Convergence 2023 (2023)
31. Sontheimer RD, "The management of dermatomyositis : current treatment options", Expert Opin Pharmacother, 5, pp.1083~1099 (2004)
32. Waldman R, "Dermatomyositis : diagnosis and treatment", J Am Acad Dermatol, 82, pp.283~296 (2020)
33. Anyanwu CO, "The systemic management of cutaneous dermatomyositis : results of a stepwise strategy", Int J Womens Dermatol, 3, pp.189~194 (2017)
34. Kohsaka H, "Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists", Mod Rheumatol, 29, pp.1~19 (2019)
35. Chen KL, "Myeloid dendritic cells are major producers of IFN-β in dermatomyositis and may contribute to hydroxychloroquine refractoriness", J Invest Dermatol, 141, pp.1906~1914 (2021)
36. Pelle MT, "Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus", Arch Dermatol, 138, pp.1231~1233 (2002)
37. Piguet V, "Dermatomyositis : a slow path towards targeted therapies or will conventional therapies prevail", Br J Dermatol, 179, pp.1233~1234 (2018)
38. Woo TY, "Cutaneous lesions of dermatomyositis are improved by hydroxychloro¬quine", J Am Acad Dermatol, 10, pp.592~600 (1984)
39. Click JW, "Methotrexate for the treatment of cutaneous dermatomyositis", J Am Acad Dermatol, 68, pp.1043~1045 (2013)
40. Hornung T, "Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions", Clin Exp Dermatol, 37, pp.139~142 (2012)
41. Kasteler JS, "Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis", J Am Acad Dermatol, 36, pp.67~71 (1997)
42. Metzger AL, "Polymyositis and dermatomyositis : combined methotrexate and corticosteroid therapy", Ann Intern Med, 81, pp.182~189 (1974)
43. Tse S, "The arthritis of inflammatory childhood myositis syndromes", J Rheumatol, 28, pp.192~197 (2001)
44. Camus P, "Interstitial lung disease induced by drugs and radiation", Respiration, 71, pp.301~326 (2004)
45. Gelber AC, "Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis : a series of 4 cases", J Rheumatol, 27, pp.1542~1545 (2000)
46. Olivo Pallo PA, "Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies : case series", Adv Rheumatol, 58, pp.34~ (2018)
47. Morganroth PA, "Mycophenolate mofetil for interstitial lung disease in dermatomyositis", Arthritis Care Res(Hoboken), 62, pp.1496~1501 (2010)
48. Tsuchiya H, "Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis", Mod Rheumatol, 24, pp.694~696 (2014)
49. Pisoni CN, "Mycophenolate mofetil treatment in resistant myositis", Rheumatology(Oxford), 46, pp.516~518 (2007)
50. Dalakas MC, "A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis", N Engl J Med, 329, pp.1993~2000 (1993)
51. Bounfour T, "Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease", J Eur Acad Dermatol Venereol, 28, pp.1150~1157 (2014)
52. Femia AN, "Intravenous immunoglobulin for refractory cutaneous dermatomyositis : a retrospective analysis from an academic medical center", J Am Acad Dermatol, 69, pp.654~657 (2013)
53. Galimberti F, "Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis", Clin Exp Dermatol, 43, pp.906~912 (2018)
54. Ludwig RJ, "Mechanisms of autoantibody-induced pathology", Front Immunol, 8, pp.603~ (2017)
55. Ardeniz Ö, "β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system", J Allergy Clin Immunol, 136, pp.392~401 (2015)
56. Roopenian DC, "FcRn : the neonatal Fc receptor comes of age", Nat Rev Immunol, 7, pp.715~725 (2007)
57. Li N, "Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases", J Clin Invest, 115, pp.3440~3450 (2005)
58. Hansen RJ, "Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor", Thromb Haemost, 88, pp.898~899 (2002)
59. Hoffmann JH, "High-dose intravenous immunoglobulin in skin autoimmune disease", Front Immunol, 10, pp.1090~ (2019)
60. Aggarwal R, "Trial of intravenous immune globulin in dermatomyositis", N Engl J Med, 387, pp.1264~1278 (2022)
61. Werth VP, "Efficacy of intravenous immunoglobulins(IVIg)in improving skin symptoms in patients with dermatomyositis : a post-hoc analysis of the ProDERM study", EClinicalMedicine, 64, pp.102234~ (2023)
62. Werth VP, "Trial of intravenous immune globulin in dermatomyositis", N Engl J Med, 388, pp.94~95 (2023)
63. Ulrichts P, "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans", J Clin Invest, 128, pp.4372~4386 (2018)
64. "A Study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA)" (2024)[URL]
65. "A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy. (ALKIVIA)" (2024)[URL]
66. Edwards JC, "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N Engl J Med, 350, pp.2572~2581 (2004)
67. Piper CJ, "CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-α", Front Immunol, 9, pp.1372~ (2018)
68. Zhen C, "Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies : a systematic review and meta-analysis", Front Immunol, 13, pp.1051609~ (2022)
69. He C, "Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis : a systematic review", Front Immunol, 12, pp.820163~ (2022)
70. Aggarwal R, "Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab", Rheumatology(Oxford), 56, pp.247~254 (2017)
71. Dinh HV, "Rituximab for the treatment of the skin manifestations of dermatomyositis : a report of 3 cases", J Am Acad Dermatol, 56, pp.148~153 (2007)
72. Chung L, "A pilot trial of rituximab in the treatment of patients with dermatomyositis", Arch Dermatol, 143, pp.763~767 (2007)
73. Müller F, "CD19-targeted CAR T cells in refractory antisynthetase syndrome", Lancet, 401, pp.815~818 (2023)
74. Pecher AC, "CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome", JAMA, 329, pp.2154~2162 (2023)
75. Müller F, "CD19 CAR T-cell therapy in autoimmune disease-a case series with follow-up", N Engl J Med, 390, pp.687~700 (2024)
76. "RESET-myositis: an open-label study to evaluate the safety and efficacy of CABA-201 in subjects with active idiopathic inflammatory myopathy" (2024)[URL]
77. "Safety and efficacy of CD19 targeted CAR-T therapy for refractory autoimmune disease" (2023)[URL]
78. Aggarwal R, "Rapid onset of response in adult dermatomyositis patients receiving anti-interferon β(PF-06823859) : results of a phase 2, double-blind, randomized, placebo-controlled study", ACR Convergence 2023 (2023)
79. Ladislau L, "JAK inhibitor improves type I interferon induced damage : proof of concept in dermatomyositis", Brain, 141, pp.1609~1621 (2018)
80. Kurtzman DJ, "Tofacitinib citrate for refractory cutaneous dermatomyositis : an alternative treatment", JAMA Dermatol, 152, pp.944~945 (2016)
81. Moghadam-Kia S, "Management of refractory cutaneous dermatomyositis : potential role of Janus kinase inhibition with tofacitinib", Rheumatology(Oxford), 58, pp.1011~1015 (2019)
82. Paik JJ, "Study of tofacitinib in refractory dermatomyositis : an open-label pilot study of ten patients", Arthritis Rheumatol, 73, pp.858~865 (2021)
83. "A study to investigate the efficacy and safety of brepocitinib in adults with dermatomyositis (VALOR)" (2024)[URL]
84. Patel MC, "Novel drugs targeting Toll-like receptors for antiviral therapy", Future Virol, 9, pp.811~829 (2014)
85. "Study of M5049 in DM and PM participants (NEPTUNIA)" (2024)[URL]
86. Maddukuri S, "Cannabinoid type 2 receptor(CB2R)distribution in dermatomyositis skin and peripheral blood mononuclear cells(PBMCs)and in vivo effects of LenabasumTM", Arthritis Res Ther, 24, pp.12~ (2022)
87. Tepper MA, "Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity", Bioorg Med Chem, 22, pp.3245~3251 (2014)
88. Robinson ES, "Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-α, and type i interferons in dermatomyositis in vitro", J Invest Dermatol, 137, pp.2445~2447 (2017)
89. Kim HJ, "Itch in dermatomyositis : the role of increased skin interleukin-31", Br J Dermatol, 179, pp.669~678 (2018)
90. Werth VP, "Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease : a randomized clinical trial", J Invest Dermatol, 142, pp.2651~2659 (2022)
91. Werth V, "Cutaneous manifestations, clinical trials, safety efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis", ACR Convergence 2022 (2022)

관련 논문AI추천